A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 25, 2022

Primary Completion Date

November 11, 2024

Study Completion Date

February 3, 2025

Conditions
Chronic Spontaneous Urticaria
Interventions
DRUG

Dupilumab

Injection solution Subcutaneous

Trial Locations (15)

10032

Columbia University Irving Medical Center Site Number : 8400003, New York

10532

Boston Childrens Health Physicians Site Number : 8400017, Hawthorne

33146

Pediatric Dermatology of Miami Site Number : 8400015, Coral Gables

37232

Monroe Carell Jr. Childrens Hospital at Vanderbilt- Site Number : 8400005, Nashville

44308

Childrens Hospital Medical Center of Akron- Site Number : 8400020, Akron

63110

Washington University School of Medicine- Site Number : 8400004, St Louis

74136

Vital Prospects Clinical Research Institute, P.C.- Site Number : 8400002, Tulsa

83706

Treasure Valley Medical Research Site Number : 8400019, Boise

45229-3026

Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400001, Cincinnati

T2W 4X9

Investigational Site Number : 1240009, Calgary

T5J 3S9

Investigational Site Number : 1240010, Edmonton

L8S1G5

Investigational Site Number : 1240007, Hamilton

H4A 3J1

Investigational Site Number : 1240001, Montreal

232-8555

Investigational Site Number : 3920001, Yokohama

514-0125

Investigational Site Number : 3920002, Tsu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY